after an encouraging pilot study , we treated 16 patients suffering from hcc , with a combination of lipiodol and epirubicin , a cytotoxic agent having an enhanced activity against hcc as compared with its parent drug doxorubicin .
C0014582
epirubicin
C0013089
doxorubicin